Jan 12, 2026 | Acquisition Cost Index (ACI), Biosimilar, Brand Name Drugs, Drug costs, High-value formulary, MedBen Rx, News, Patient assistance program, Pharmacogenomics, Rx Costs, Rx prices
Pharmaceutical manufacturers are planning to raise list prices on at least 350 brand-name medications in the United States beginning in 2026, up from 250 drugs last year, according to new data from health care research firm 3 Axis Advisors. These increases reflect...
Dec 1, 2025 | Acquisition Cost Index (ACI), Benefits preservation, Biosimilar, Case Study, Cost Savings, MedBen Rx, Savings
A new MedBen Rx client realized $1.19 million in combined plan and member savings in their first year – a 45.7% reduction, surpassing the $1.05 million projected savings. Per-member-per-month (PMPM) pharmacy costs tell the story: $233 under the previous PBM vs. just...
Jul 29, 2025 | Biologics, Biosimilar, Cost Savings, MedBen Rx, Pharmacies, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs, Savings
The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake....
May 19, 2025 | Biosimilar, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
Apr 21, 2025 | Biosimilar, Cost Savings, Drug costs, Humira, Rx Costs, Savings, Stelara
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
Oct 15, 2024 | Benefits preservation, Biosimilar, Claims, Cost Savings, Drug costs, Rx Costs, Savings, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
